# OnCo record paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017" ;
  schema:name "Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy"@en ;
  schema:alternateName "IELSG-19"@en, "Zucca 2017"@en ;
  schema:description "The first randomised trial of first-line drug treatment for MALT lymphoma: the combination of an old tablet and an antibody beat either alone on relapse, and nobody lived longer."@en ;
  schema:url <https://onco.cc/key-papers/paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2016.70.6994>, <https://pubmed.ncbi.nlm.nih.gov/28355112/>, <https://europepmc.org/article/MED/28355112> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1200/JCO.2016.70.6994> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Zucca E, Conconi A, Martinelli G, et al." ;
  onco:related <https://onco.cc/key-papers/paper-wotherspoon-h-pylori-malt-lancet-1993/>, <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:targets <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/ielsg/> ;
  onco:trials <https://onco.cc/trials/ielsg-19/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-trial-enrolment/> ;
  onco:journals <https://onco.cc/journals/jco/> .